Abstract
THE PHARMACEUTICAL industry has formed an eight-member Commission on Medicine for Treating Drug Dependence and Abuse to work with government agencies in expediting promising pharmacologic approaches to the treatment of addiction. It is chaired by Harry M. Meyer, Jr, MD, president, Medical Research Division, American Cyanamid Company, Wayne, NJ. Frederick K. Goodwin, MD, administrator, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Md, points to what he calls virtual explosion of knowledge in the understanding of neurochemical mechanisms of behavior. What has been called the psychopharmacological revolution permits us to target therapeutic compounds with ever-increasing specificity, he says. We have advanced from relying on the observations of drug effects on a particular condition to a capacity to rationally design compounds that will redress the specific neurochemical deficiencies associated with illnesses such as addiction, Goodwin says. The commission's goals, as Goodwin sees them, are to discover possibly effective agents that
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
